DTCC Proposes Shortening US Trading Settlement Cycle To T+1: Here’s Why That’s Important
Wayne Duggan, Benzinga, 24 February 2021
ROBERT STEELE: This article is such crap. As if DTCC had not willfully covered up $100 trillion in naked short counterfeit sales these past 15-20 years. Until DTCC is given a porcupine enema and we sent DOJ, FBI, and US Southern District Attorneys to jail for life for treason — enabling foreign collusion and domestic crime against the US economy — for life, this will not change.
Short Sellers Still Targeting Retail, Biotech ETFs
Wayne Duggan, 18 February 2021
After a huge second half of 2020, the S&P 500 is off to another hot start to 2021. With stock market valuations getting more bloated by the week, there are plenty of skeptics that believe certain stocks and sectors have come too far too fast.
There is currently $244 billion in aggregate domestic ETF short interest, according to S3 Partners analyst Ihor Dusaniwsky. Over the past month, Dusaniwsky said short sellers have increased their exposure by about $14 billion. Continue reading “Article: Short Sellers Still Targeting Retail, Biotech ETFs”
$1,000, 5 Years Later: Valeant’s Wild Ride To Bausch Health
Wayne Duggan, 16 February 2021
Investors who have owned stocks since 2016 generally have experienced some big gains. In fact, the SPDR S&P 500
SPY total return in the last five years is 131.9%. But there is no question some big-name stocks performed better than others along the way.
Valeant’s Downfall: One company that has been a disastrous investment in the last five years is health care company Bausch Health Companies Inc BHC 0.06% , formerly known as Valeant Pharmaceuticals. Not only has Bausch lagged the overall market in the last five years, Valeant represents one of the most infamous stock collapses in recent decades. Bausch produces pharmaceutical products and generic drugs. It is also the parent company of eye health products leader Bausch & Lomb.
Continue reading “Article: $1,000, 5 Years Later: Valeant’s Wild Ride To Bausch Health”
Citron Calls Bausch Health — Formerly Valeant — The ‘Textbook Turnaround’
Wayne Duggan, 15 October 2019
Three years after Citron Research called Valeant the “pharmaceutical Enron,” the firm said Tuesday that it’s time to give Valeant successor Bausch Health Companies Inc BHC 0.06% the credit it is due for its rebranding and turnaround efforts.
On Tuesday, Citron Research’s Andrew Left said CEO Joe Papa has done a spectacular job since taking over less than four years ago. In the past three years alone, management has paid down about $8 billion in debt, vastly improving the company’s balance sheet and putting them in a position of financial flexibility.
“In 2019, the debt has become manageable and the company is gaining momentum with recent, successful launches of new drugs, consistent with its ‘pivot to offense,’” Left said.
Continue reading “Article: Citron Calls Bausch Health — Formerly Valeant — The ‘Textbook Turnaround’”
Short Sellers Piling Into Chinese Stocks As Trade Tensions Rise
Wayne Duggan, 19 September 2019
Trade tensions between China and the U.S. are once again on the rise over President Donald Trump’s threats to ban TikTok and WeChat in the U.S. starting on Sunday. With the November election now only about six weeks away, S3 Partners analyst Ihor Dusaniwsky said short sellers are targeting Chinese stocks in a major way.
Dusaniwsky said China and Hong Kong short interest now totals $104 billion, an increase of $2.03 billion in the past month. The dispute between Trump and China over TikTok could be a preview of what’s to come between now and the election, and short sellers seem to believe Chinese stocks could suffer. Continue reading “Article: Short Sellers Piling Into Chinese Stocks As Trade Tensions Rise”
Cronos Group, Analyst Respond To Citron’s Short Report
Wayne Duggan, 31 August 2018
Citron’s Andrew Left said Thursday morning that Cronos’ agreements are so small that they wouldn’t even come close to justifying the huge gains in the company’s market cap. Left said Cronos lags its Canadian cannabis peers in sales, trades at a steep premium to Canopy Growth Corp CGC 0.42% (which has a beverage deal in place), has a history of product recalls, has no U.S. business and is spending practically nothing on research and development.
“When looking at Cronos relative to other cannabis stocks that have yet to receive a ‘beverage deal,’ Cronos’ sky high valuation looks completely out of whack with fundamentals,” Left said.
Continue reading “Article: Cronos Group, Analyst Respond To Citron’s Short Report”